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Case Presentation
A 63-year-old white Caucasian woman female showed rapidly extending ischaemic-necrotic 
lesions to the lower limbs. She had history of smoking and especially she was swallowing anticoagulant 
oral therapy based on acenocumarol by paroxystic fibrillation. A skin biopsy showed a vasculitis 
with leukocytoclastic features without any vessel calcifications. At the beginning the diagnosis was 
calciphylaxis for the tipical plurime skin necrosis features. Her laboratory data are as follows: serum 
parathyroid hormone (PTH), 260 pg/mL; ionized calcium, 4.2 mg/dL; serum phosphorus, 4.3 mg/
dL; ANCA and ANA: negative; coagulation Free Protein S repeatedly low <68%; serum albumin, 
3.2 g/dL. Which risk factors was determinant? Which treatment strategies should be considered? 
Would this disease be considered a validate calciphylaxis?
Introduction
Patients with chronic kidney failure (CKD) develop extra skeletal calcifications causing 
increased vascular stiffness, and much more risks of cardiovascular disease and increased mortality 
[1]. An increasing number of risk factors for vascular calcification are involved CKD: uremic status 
itself, the chronological age, sex, inflammation, abnormalities of mineral metabolism, concomitant 
diseases such as diabetes and blood hypertension [2]. Calcific uremic arteriolopathy (CUA), more 
commonly, although at times inappropriately known as calciphylaxis, is a rare morbid condition 
manifested prevalently, although not exclusively, in patients affected by advanced chronic kidney 
disease (CKD) [3-7]. CUA is a severe, potentially fatal, and highly disabling disorder affecting 
approximately 1- 4% of the population with CKD [3] with a high mortality rate in approx. 60-80% 
of patients [8]. The mortality rate almost doubles in subjects presenting with ulcerative skin lesions. 
Death is mainly due to sepsis following infection of the necrotic skin lesions. Overall estimated 
survival rates at 1 and 5 years are 45% and 35%, respectively.
The clinical picture is characterized by painful skin lesions that tend to necrotize with subsequent 
Does Oral Anticoagulant Therapy (OAT) Play a Key Role 
in Triggering and Maintaining Calcyphilaxis? A Case 
Report Proposing a New Etiological and Nosological 
Review
OPEN ACCESS
 *Correspondence:
Piergiorgio Bolasco, Department 
of Nephrology, Territorial Unit of 
Nephrology and Dialysis, ASL of 
Cagliari, via Turati 4/C1, 09045 
Quartu Sant’Elena (CA), Italy, Tel: 
+390706097335; Fax: +390706097340;
E-mail: pg.bolasco@tin.it
Received Date: 18 May 2016
Accepted Date: 28 Oct 2016
Published Date: 15 Nov 2016
Citation: 
Murtas S, Palomba M, Cozzolino M, 
Bolasco P. Does Oral Anticoagulant 
Therapy (OAT) Play a Key Role 
in Triggering and Maintaining 
Calcyphilaxis? A Case Report 
Proposing a New Etiological and 
Nosological Review. Remed Open 
Access. 2016; 1: 1025.
Copyright © 2016 Bolasco P. This is 
an open access article distributed under 
the Creative Commons Attribution 
License, which permits unrestricted 
use, distribution, and reproduction in 
any medium, provided the original work 
is properly cited.
Case Report
Published: 15 Nov, 2016
Abstract
Calcific uremic arteriolopathy (CUA) is a rare but very serious morbid condition often observed 
during secondary hyperparathyroidism (HPTS). CUA affected patients by advanced chronic kidney 
disease (CKD). The Authors report a clinic case of a 63-year female diabetic patient on chronic 
hemodialysis that suddenly showed progressive necrotic cutaneous lesions similar to CUA. The 
status HPTS was in good control. This case led the authors to consider different etiological causes 
especially when vascular calcification. In the patient the main noxae could be the anticoagulant oral 
therapy (AOT) together smoking and inflammation induced by a severe malnutrition. Therapies 
proposals were sodium thiosulfate, based amino acids nutrition, an accurate and constant surgical 
medication of necrotic injuries. After the complete healing of skin lesions and good correction of 
nutritional status, the Authors asserted that OAT especially if associated with malnutrition smoking 
and diabetes can lead to necrotic lesions similar but not classifiable as calciphylaxis.
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ulcers or gangrene, at times requiring amputation (Figure 1). The 
development of infections resulting in sepsis or death is a frequent 
occurrence.
Regrettably, the etiopathogenesis of CUA remains largely 
unknown, and the numerous pathogenetic hypotheses put forward 
tend not only to complicate treatment but also to render it somewhat 
empirical [6].
Indeed, CUA is a complex disorder generated by a multi-factorial 
aetiology. With a view to taking into consideration further hypotheses 
and etiological causes, as well as to avoid an inappropriate nosological 
generalization of the term “calcyphilaxis” (Phylakterion: safeguard, 
such as a tissue hypersensivity reaction to calcium precipitation), it 
would like to highlight alternative clinical hypothesis inspired by our 
clinical case [9].
Clinical aspects, ethiological and diagnosis factors
In CUA the skin lesions are manifested in a characteristic manner 
and present a singular evolution phases. After pruritus the potential 
concomitant presentation of bullous alterations is indicative of 
the future onset of necrosis. At more advanced stages the affected 
areas extend and transform into hard black eschars with a tendency 
towards deep ulceration (Figure 2), at times reaching the muscle 
fascia. Gangrene may be observed (although amputation is rarely 
required) in the fingers and toes, and frequently in the penis. In case 
of healing it could have a progressive regression of the lesions thanks 
to frequent and accurate medications with removal of necrotizing 
lesions and afterwards, such as our clinic case, the appearance of 
granulation tissues until a full scar formation (Figure 3 and 4). 
Numerous dermatological conditions should be taken into account 
during the initial stages. Differential diagnosis should be undertaken 
prevalently with: antiphospholipid syndrome, radiation arteritis, 
vasculitis, dystrophic calcification, cholesterol embolism, panniculitis, 
purpura fulminans, warfarin necrosis, heparin necrosis, nephrogenic 
systemic fibrosis, cutaneous anthrax, gangrenous pyoderma, oxalate 
artheriopathy, obliterating arteriosclerotic vascular disease, [10,11] 
(Table 1). In the present case we excluded the CKD-MBD with 
vascular calcifications of secondary hyperparathyroidism (SHPT). 
Accordingly, we focussed our search on causes other than those 
routinely described in literature [9] summarized in table 1. In fact 
although the mechanisms pathogenesis of the process of vascular 
calcification is not fully defined, it isn’t generally accepted just a 
passive process deposition of phosphate and calcium crystals. But 
a process actively and finely tuned to the level of the arterial wall, 
involving both endothelial cells, smooth muscle cells of vascular 
tunica media, vascular smooth muscle cells (VSMCs). In pathological 
conditions such as CKD, however, can change the VSMCs phenotype 
and it could turn into cells very similar to osteoblasts. The VSMCs 
synthesize proteins that are involved in the mechanisms of 
prevention of vascular calcification; in fact Protective Anti-Calcifying 
like the Matrix GLA protein (MGP) is one the most important key in 
preventing vascular calcification [12].
Given the relative rarity of calcyphilaxis there are no systematic 
analyzes of standardized diagnostic tests. Biomarkers and radiological 
tests, non invasive imaging tools (for example, simple x-rays and 
bone scans) and circulating Fetuin A have been reported to help in 
the diagnosis of calcyphilaxis. However, none of these instruments 
have been systematically evaluated and are not recommended for 
clinical use at this time [5,13-18]. Laboratory tests should highlight 
the potential risk factors: renal function, parameters of mineral 
metabolism such as serum calcium and phosphorus, alkaline 
phosphatase, intact PTH, and 25-hydroxyvitamin D, assessment 
of liver function and the evaluation of the usual inflammatory and 
Figure 1: Necrotic lesions of left lower limb.
Figure 2: Necrotic lesions of right lower limb.
Figure 3: Initial healing of lesion of left leg after several specific medication: 
note absence of necrosis and appearance of granulation tissue (yellow layer).
Figure 4: Complete healing of lesion; skin scares remain.
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infectious analysis, evaluation of coagulation (prothrombin time 
and partial thromboplastin time, protein C, S antithrombin III and 
antiphospholipid antibodies) and specific checks in case of suspect of 
a immunological pathology, lipids abnormalities and others.
Risks and benefits of skin biopsy
Skin biopsy is a minimally invasive intervention that is achieved 
under local anesthesia inside of the surgeries studies, thus without the 
need to resort to hospitalization. There are four different types of this 
intervention depending on the portion of the skin removed and the 
methodology by which is taken: Excisional: in this case it is removed 
the entire portion of the skin affected by the pathology is suspected; 
Incisional: it is taken a diamond of skin; Punch: it is extracted a 
small portion of skin with an engraving cylinder; Shave: come off a 
thin flap of skin with tangential cut. Skin biopsy is very necessary 
in hemodialysis patients when there are more than, two painful 
non treatable skin ulcers irrespective of their localization [17]. The 
risks of biopsy may be: ulcerations, superimposed infection, spread 
of new lesions, haemorrhages and further necrosis induction; for 
these reasons it is necessary a monitoring with frequent medications 
of the wound-biopsy under antibiotics coverage especially 
against Staphylococcus families. Because the histopathological 
pathognomonic and ethimological findings is the calcification of the 
middle layer of the wall of arterioles showed only by silver nitrate 
(method "Von Kossa") or with red Alizarin, the biopsy is the only way 
to define a necrotic lesion such a “ true calcyphilaxis” (Figure 5) and 
to exclude other entities such as vasculitis. 
The risk is tiny but very important rather than a rough diagnosis 
and so an unsuccessful specific therapy. Calciphylaxis comprises two 
separate processes, firstly a pre-existent and/or transitory calcification 
of subcutaneous arterioles, and second infarctions of subcutaneous 
adipose tissue (panniculus adiposus) and skin [19]. Although subtle, 
perieccrine calcification may aid the diagnosis of calcyphilaxis in 
settings in which typical vascular and extravascular calcifications 
have not been identified. However, the true pathognomic role of skin 
biopsy remains uncertain [20,21].
Frequent etiological factors
Secondary hyperparathyroidism or high turnover bone disease: 
The impellent need for close monitoring of mineral metabolism is well 
acknowledged: maintenance of the calcium-phosphorus product <55, 
phosphorus ranging between 2.7 and 4.6 mg/dL. The administration 
solely of non-calcium based phosphate binders containing sevelamer 
and lanthanum carbonate is paramount. PTH levels are regulated by 
means of cinacalcet administration and by avoiding vitamin D and 
derivatives.
Undeniably, the onset of a large number of cases may be SHPT-
linked; in our opinion, this definition should be limited solely to 
severe cases of CKD-MBD [22].
Low bone turnover disease: In the German calcyphilaxis registry 
(www.calciphylaxie.de) a total of 253 patients had currently been 
included from 2006 to 2015; in 217 patients KDIGO target were 8% 
above range, 47% within range, and 47% below during calcyphilaxis 
manifestation. There is a prevalence of female gender. This observation 
could mean that patients with a dynamic bone disease had a more risk 
of vascular calcification rather than these with high bone turnover 
disease but phosphorus in 217 patients has a great importance 
(KDIGO target 60% above, 34% within and 6% below) [23].
Bad Nutrition: Recent clinical and experimental data have 
shown how the protein metabolism is largely impaired in patients 
with chronic diseases such as heart failure [9,24,25].
Smoking: is considered a major risk factor for cardiovascular 
events in the general population. A prospective study has previously 
demonstrated an increased incidence of new-onset congestive heart 
failure, new-onset peripheral vascular diseases, and mortality among 
dialysis patients who smoke [26]. The increased risk of cardiovascular 
events may result from a higher level of fibrinogen and a higher 
systolic blood pressure in smokers than in non-smokers on dialysis. 
A meta-analysis also showed a significantly higher risk of mortality in 
True Calciphylaxis Calciphylaxis-like
Phases 1) pruritus, 2) cutaneous laminar erythema, 3) painful ulceration, 4) necrosis.
likely in OAT skin necrosis but different onset outcome: dystrophic calcification, 
cholesterol embolism, panniculitis, purpura fulminans, nephrogenic systemic 
fibrosis, cutaneous anthrax, oxalate artheriopathy gangrenous pyoderma, 
obliterating arteriosclerotic vascular disease, antiphospholipid syndrome, 
radiation arteritis;
Hyperparathyroidism especially in low and high turnover bone disease; no influence on the diagnosis
Ddifferent limits
a) Distal: lower extremities b) proximal: 
trunk, thighs (especially fat), buttocks, 
abdomen, penis; (more than two skin pain 
ulcers)
likely in OAT skin necrosis but differences in: dystrophic calcification, 
cholesterol embolism, injection site necrosis in heparin necrosis, nephrogenic 
systemic fibrosis, nephrogenic systemic, oxalate artheriopathy, gangrenous 
pyoderma, cutaneous anthrax fibrosis, obliterating arteriosclerotic vascular 
disease, antiphospholipid syndrome, radiation arteritis.
Histomorphological findings
inside tunica media and internal of 
small/medium size vessels mural and 
extravascular calcifications with thrombosis 
and often concentric stenosis;
no vessel calcifications in all pathology except but different in: calcification 
histomorphology in dystrophic calcification , histological differences in 
rare calcification panniculitis, obliterating arteriosclerotic vascular disease, 
antiphospholipid syndrome, radiation arteritis;
Pathognomic and/or hematological 
and microbiological image study nothing
in several pathologies there are specific markers like: vasculitis, allergic 
data, nephrogenic systemic fibrosis gadolinium-linked, cutaneous anthrax, 
gangrenous, oxalate artheriopathy pyoderma, antiphospholipid syndrome;
Table 1: Differential diagnosis of necrotic skin lesions in hemodialysis patient.
Figure 5: No evident vascular calcification with von Kossa stain; note 
vasculitis reaction of  surrounding  and inside wall vessels.
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dialysis patients who smoke. These studies confirm that the patients 
who are current smokers are associated with increased mortality. The 
impact of smoking on mortality found in our study, HR=19.3, is much 
higher than that reported previously. Vascular dysfunction induced 
by smoking is initiated by reduced nitric oxide (NO) bioavailability 
and further by the increased expression of adhesion molecules and 
subsequent endothelial dysfunction. Smoking-induced increased 
adherence of platelets and macrophages provokes the development 
of a procoagulant and inflammatory environment [27]. Our finding 
supports the K-DOQI guidelines advocating regular counselling and 
encouragement for ESRD patients to stop smoking.
Role of anticoagulant therapy
In our case the use of OAT [28] was decisive, with smoking and 
inflammation-malnutrition acting as aggravating factors. Indeed, 
the most well-known vitamin K-dependent proteins (KDPs) are 
coagulant factors II, VII, IX, and X. In Brandeburg communication 
[23] by German Registry Analysis 2015 the beyond of 50% of patients 
assumed vitamin K antagonist but it didn’t known how many patients 
were made the histological calcification pattern. By interfering with 
this carboxylation process, warfarin and/or acenocumarol have 
become the mainstay of anticoagulant therapy. In particular, two 
important VKDPs, Matrix Gla protein (MGP) and Growth Arrest 
Specific gene 6 (Gas-6) protein were involved [29]. The importance 
of the roles played by these proteins in vascular biology is currently 
undergoing extensive investigation. MGP acts primarily as a vascular 
calcification inhibitor. Gas-6 affects vascular smooth muscle cell 
movement and apoptosis. Together, these proteins constitute a new 
mechanism of local vascular regulation, in which the blood vessel 
defends itself against injury and participates in self-repair. A failure 
of these local mechanisms might at times be observed, although not 
necessarily tending towards vascular calcification [30]. The MGP is 
part of the family of proteins dependent on vitamin K, is synthesized 
by chondrocytes and by VSMCs and requires a gamma-carboxylation 
post-translational activity to reach a complete biological action. 
Warfarin is a vitamin K antagonist that interferes with the activation 
of the MGP precisely in this gamma-glutamyl carboxylation [31]. 
Vascular smooth muscle cells develop apoptotic bodies prior to 
forming calcium crystals; apoptosis may thus represent the critical 
first step in the process, although calcification may be a secondary, 
although not mandatory, phenomenon of dying cells [32]. However, 
a high clinical suspicion should be maintained, and adequate 
therapies, particularly with thiosulfate, implemented even when 
skin biopsy fails to confirm the involvement of vascular calcification 
[33]. Skin necrosis being TAO is also a known side effect. This rare 
complication usually occurs between the third and the eighth day 
therapy, and is caused by extensive thrombosis of the veins and 
capillaries of the subcutaneous adipose tissue. It manifests itself, 
especially at the expense of areas with abundant subcutaneous fat, 
such as breasts, buttocks, thighs, abdomen and it is little discernable 
to the true calcyphilaxis. The patients who have genetic deficiency 
of protein C and S, antithrombin III, activated protein C resistance 
with or without the factor V Leiden mutation, the mutation G20210A 
of prothrombin, the antiphospholipid syndrome, seem most at risk. 
Histologically detects the occlusion of the capillaries subcutaneous 
and dermal by fibrin thrombi in the absence of a frank vasculitis with 
little or no deposit of the complement C3 into the dermoephitelial 
junction. The administration of vitamin K and heparin may 
prevent progression to frank necrosis, otherwise you need surgical 
treatment. There is still no adequate clinical experience in patients 
undergoing hemodialysis using new oral anticoagulant that directly 
inhibit thrombin (dabigatran) or factor X a such as rivaroxaban and 
apixaban [34].
Rule of Therapies
Sodium thiosulfate (STS)
The proposed mechanism of action for STS is not yet fully 
known; the drug however appears to be capable of dissolving calcium 
salts deposited in tissues, transforming them into soluble calcium 
thiosulfate. Doses vary from 5 to 25 grams i.v three or four times a 
week for a period ranging from 6 to 24 months. However, the efficacy 
of thiosulfate may also be independent of the protective effect of 
crystal load, and at least in part due to its antioxidant properties [35]. 
Furthermore, the vasodilatory action of sodium thiosulfate on arterial 
circulation should not be underestimated [36].
Nutrition
The great important of bad nutrition explaining the increasing 
interest in a mixture of Essential Amino Acids (AEE) which has 
proved to be particularly useful in treating the aminoacidic “quake” 
typical of uremic status. This mixture is composed with leucine, 
lysine, isoleucine, valine, threonine, cystine, histidine, phenylalanine, 
methionine, tyrosine and tryptophan. The stimulatory mechanism 
of protein synthesis is attributable to the stimulation of the ancestral 
pathway m-TOR-kinases independently by insulin. This pathway 
could mainly activated in conditions of insulin-resistance as can be 
seen during the course of chronic renal failure. The mixture of amino 
acids investigated is particularly rich in branched-chain amino acids 
which are transported to the liver for gluconeogenetic purposes and 
to the intestine as energetic substrate strong stimulators of glutamine 
and alanine synthesis [25]. However, the extent of impairment is 
frequently underestimated or ignored by clinicians, who fail to 
consider the possibility of prescribing amino acid therapy, thus 
resulting in a progressive loss of proteins in the body, increased 
morbidity, hospital stay and mortality. In the same way as patients 
with chronic heart failure, a considerable number of hemodialysis 
patients may be affected by muscular under perfusion, consequently 
resulting in severe impairment of enzyme mitochondrial activity 
and difficulty to resynthesize proteins especially for cells designated 
to the local and systemic immunological defence [38]. Moreover, 
the above mentioned literature has provided ample demonstration 
that the highest degree of penetration and intracellular insulin 
action is achieved by essential amino acids. Unfortunately, although 
the above has been repeatedly confirmed in cardiological and 
neurological literature, there has to date been a scarcity of interest 
from nephrologists [39,40].
Surgical medication
A multidisciplinary approach should be adopted both in the 
case of CUA-induced and other types of necrotizing lesions, with 
particular focus on the local treatment of skin lesions aimed at 
preventing the onset of local and/or systemic infection. Additionally, 
strict metabolic monitoring should be established in an attempt to 
halt the inevitable hypercatabolism produced by inflammation and 
reactivate the immune response compromised by malnutrition [37-
39]. Medication represents one of the fundamental issues in healing 
this type of lesion; one of the best are TIME rule procedures (acronym 
of Tissue, Infection, Moisture Imbalance, Epidermal margin) should 
be rigorously applied [40]. The lesion should be combated both 
systemically and locally through the regenerating action of the 
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amino acids, particularly in diabetes. Diabetic patients may benefit 
considerably from use of essential amino acids, which promote cell 
sensitivity to the effect of exogenous and/or endogenous insulin [25]. 
Essential amino acid-based creams composed by glicine, L-proline, 
L-leucine and L-lisine may represent one of the key players in healing 
lesions by regenerating granulation tissues in the presence of an 
evident state of malnutrition. An inappropriate use of disinfectants 
inside of the lesion should be avoided and may result in necrosis of 
the abovementioned granulation tissues pivotal to the regeneration of 
all overlying cutaneous layers.
Calcimimetic
In the EVOLVE trial 24 of 3,861 enrolled patients developed 
calcyphilaxis: six in cinacalcet arms and 18 in the placebo group. 
Cinacalcet could produce a 69%–75% of therapeutic risk reduction 
by cinacalcet [41].
Other therapeutic strategies
The confirmation of utility of bisphosphonate treatment lack 
the support of relevant comparative studies [42]. The positive effect 
of hyperbaric oxygen therapy remains to be confirmed, and the 
potential risk of eliciting tissue superoxide mechanisms assessed; 
further studies should be carried out to confirm the significance 
of the effect produced on tissues and cells by an excess of O2 [43]. 
Intensifying dialytic therapy could be a double-edge sword because of 
the probable danger due to the balance by dialysate/infusate calcium 
concentration and it don’t exist confirmation studies at the moment.
Conclusion
An extensive experience in the field has led us to consider a wide 
range of diagnostic and therapeutic horizons (Table 1). In numerous 
cases reported in literature skin biopsies were not carried out and/
or the presence of vascular calcifications demonstrated; likewise, no 
reference was made to the use of drugs routinely prescribed in OAT. 
Fortunately it was recently added to the web network the European 
register on calciphylaxis (www.calciphylaxis.net). It would take into 
account and emphasized important data such: OAT, nutritional 
status (BMI, albumin and serum total protein) smoke and could be 
begun made on evidence a sub-classification different of CUA to 
classify in several clinical cases the term of “real calciphylaxis”. In fact 
in our case OAT could be considered a triggering and/or maintaining 
cause of the ischemic lesions. In some ways we cannot diagnose the 
necrosis due exclusive to warfarin alone for reasons like the late onset 
and the characteristic histology picture. It couldn’t be proper to 
define a sure etymologically CUA right only for the total histological 
lack of calcifications. In fact in several publications the typical 
histologically diagnosis was not confirmed or was unclear [3,6,44-
46]. It is not particularly difficult distinguish the other pathologies 
causing skin necrosis thanks to very different immunological and/
or microbiological triggering noxae, no showed clinical aspect of 
the progression phases except OAT calcyphilaxis-like (Table 1). So 
it may be appropriate to redefine “calcyphilaxis-like” the pathologies 
similar to the black necrotizing panniculitis or cellulitis. However, the 
fundamental therapeutic strategies that should never be overlooked 
irrespective of the cause of the necrotic lesion and/or calcification 
deposits. The main strategies have always to include: hanging as soon 
as possible OAT, use of sodium thiosulfate, particularly in view of 
its significant adjunctive vasodilatatory and antioxidant properties 
on the small vessels, mandatory treatment of protein-caloric 
malnutrition and use of an accurate calcium kinetic control and a 
hard specific regenerative medication. Appropriate control of diabetes 
and smoking cessation should be always achieved. To conclude, oral 
anticoagulant therapy shouldn’t be ever underestimated in front of all 
suspicious suspect skin lesions.
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